Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials01:16

Clinical Trials

11.2K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
11.2K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

548
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
548
Clinical Trials: Overview01:11

Clinical Trials: Overview

5.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.4K
Statistical Software for Data Analysis and Clinical Trials01:12

Statistical Software for Data Analysis and Clinical Trials

1.9K
Statistical software is pivotal in data analysis and clinical trials by providing tools to analyze data, draw conclusions, and make predictions. These software packages range from simple data management applications to complex analytical platforms, supporting various statistical tests, models, and simulation techniques. Their significance lies in their ability to handle vast amounts of data with precision and efficiency, enabling researchers to validate hypotheses, identify trends, and make...
1.9K
Study Design in Statistics01:15

Study Design in Statistics

10.3K
A study design is a set of techniques that allow a researcher to collect and analyze data from different variables defined for a specific research problem. Statistics is commonly for effective study design and more robust experiments,
Does aspirin reduce the risk of heart attacks? Is one brand of fertilizer more effective at growing roses than another? Is fatigue as dangerous to a driver as the influence of alcohol? Questions like these are answered using randomized experiments with proper...
10.3K
Biostatistics: Overview01:20

Biostatistics: Overview

1.1K
Biostatistics plays a crucial role in understanding and analyzing data in healthcare and biology. Biostatisticians conduct experiments, gather evidence, and draw meaningful conclusions using statistical methods and techniques. Different variables form the foundation of biostatistical analysis, allowing researchers to understand and interpret data effectively. These variables are classified into different types, each serving a specific purpose in statistical analysis.
Discrete variables are...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of clinical utility in emulated clinical trials.

European journal of epidemiology·2026
Same author

Correction to "Propensity weighting plus adjustment in proportional hazards model is not doubly robust," by Erin E. Gabriel, Michael C. Sachs, Ingeborg Waernbaum, Els Goetghebeur, Paul F. Blanche, Stijn Vansteelandt, Arvid Sjölander, and Thomas Scheike; Volume 80, Issue 3, September 2024, https://doi.org/10.1093/biomtc/ujae069.

Biometrics·2025
Same author

The next generation of regression standardization with the R package stdReg2.

Annals of epidemiology·2025
Same author

Response to Dai et al.

The American journal of gastroenterology·2024
Same author

The impact of coarsening an exposure on partial identifiability in instrumental variable settings.

Biostatistics (Oxford, England)·2024
Same author

Inflammatory plasma protein levels are elevated years before sarcoidosis diagnosis: a nested case-control study in Sweden.

The European respiratory journal·2024
Same journal

Toxicity management in thoracic chemoradioimmunotherapy: pirfenidone for low grade pneumonitis and lung fibrosis.

Chinese clinical oncology·2026
Same journal

Can recurrence-free survival replace overall survival for resectable esophageal cancer?

Chinese clinical oncology·2026
Same journal

Venetoclax with intensive chemotherapy in acute myeloid leukemia.

Chinese clinical oncology·2026
Same journal

Network pharmacology of Sijunzi decoction in pancreatic cancer.

Chinese clinical oncology·2026
Same journal

Adjuvant CDK4/6 inhibitors and novel therapies in early breast cancer: lessons from monarchE overall survival data.

Chinese clinical oncology·2026
Same journal

Efficacy and safety of TAS-102 followed by regorafenib or reverse sequence in later-line treatment of metastatic colorectal cancer: a systematic review and meta-analysis.

Chinese clinical oncology·2026
See all related articles

Related Experiment Video

Updated: Apr 3, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.5K

Statistical principles for omics-based clinical trials.

Michael C Sachs1

  • 1National Cancer Institute, Biometric Research Branch, 9609 Medical Center Drive, Room 5W114, MSC 9735, Bethesda, MD 20892-9735, USA. michael.sachs@nih.gov.

Chinese Clinical Oncology
|September 27, 2015
PubMed
Summary
This summary is machine-generated.

High-dimensional omics data holds promise for personalized cancer therapy. Validating these molecular tests and demonstrating their clinical utility are crucial steps for improving patient outcomes.

Keywords:
Genomicspersonalized medicinepredictive biomarkerstatistics

More Related Videos

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management
08:01

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management

Published on: November 30, 2022

5.9K
In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.4K

Related Experiment Videos

Last Updated: Apr 3, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.5K
Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management
08:01

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management

Published on: November 30, 2022

5.9K
In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.4K

Area of Science:

  • Biomolecular analysis
  • Genomic medicine
  • Translational research

Background:

  • High-throughput technologies generate vast molecular data (omics data) from tissue samples.
  • Omics data offers potential for personalized medicine, predicting patient prognosis and treatment response.
  • The goal is to tailor therapies to individual tumor molecular profiles for improved health outcomes.

Purpose of the Study:

  • To review statistical considerations for validating and implementing omics-based tests in clinical settings.
  • To address challenges in developing and evaluating omics tests for personalized cancer treatment.
  • To highlight the importance of demonstrating clinical utility for omics-driven therapeutic decisions.

Main Methods:

  • Discussion of statistical methodologies for omics data analysis.
  • Review of validation and reproducibility requirements for clinical assays.
  • Examination of algorithmic test development and unbiased evaluation strategies.
  • Emphasis on clinical utility assessment to prove improved patient outcomes.

Main Results:

  • Identification of key statistical challenges at each stage of omics test development and implementation.
  • Highlighting the need for rigorous validation, reproducibility, and unbiased evaluation.
  • Underscoring the critical step of demonstrating clinical utility to justify test adoption.
  • Addressing the complexities of high-dimensional omics data in clinical decision-making.

Conclusions:

  • Successful integration of omics data into clinical practice requires overcoming significant statistical and logistical hurdles.
  • Rigorous validation and demonstration of clinical utility are paramount for realizing the potential of personalized medicine.
  • Addressing the statistical challenges in handling high-dimensional omics data is essential for advancing precision oncology.